Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorGarcia-Castano, A.
dc.contributor.authorGonzalez-Barrallo, I.
dc.contributor.authorCastellon Rubio, V. E.
dc.contributor.authorMedina Martinez, J.
dc.contributor.authorManzano Mozo, J. L.
dc.contributor.authorMujika, K.
dc.contributor.authorMajem Tarruella, M.
dc.contributor.authorAguado de La Rosa, C.
dc.contributor.authorCabrera Suarez, M. A.
dc.contributor.authorPalacio, I.
dc.contributor.authorOsterloh, L.
dc.contributor.authorMartinez Fernandez, A.
dc.contributor.authoraffiliation[Garcia-Castano, A.] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
dc.contributor.authoraffiliation[Gonzalez-Barrallo, I.] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Castellon Rubio, V. E.] Hosp Univ Torrecardenas, Med Oncol, Almeria, Spain
dc.contributor.authoraffiliation[Medina Martinez, J.] Hosp Virgen de la Salud, Med Oncol, Toledo, Spain
dc.contributor.authoraffiliation[Manzano Mozo, J. L.] Germans Trias & Pujol Univ Hosp HUGTiP, Badalona Appl Res Grp Oncol B ARGO, Catalan Inst Oncol ICO Badalona, Med Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Mujika, K.] UGC Oncol Gipuzkoa HU Donostia Onkol, Med Oncol, Donostia San Sebastian, Spain
dc.contributor.authoraffiliation[Majem Tarruella, M.] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Aguado de La Rosa, C.] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Cabrera Suarez, M. A.] Hosp Univ Nuestra Senora Candelaria, Med Oncol, Santa Cruz De Tenerife, CA, Spain
dc.contributor.authoraffiliation[Palacio, I.] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain
dc.contributor.authoraffiliation[Osterloh, L.] Novartis Farmaceut SA, Med Affairs, Barcelona, Spain
dc.contributor.authoraffiliation[Martinez Fernandez, A.] Novartis Farmaceut SA, Med Affairs, Barcelona, Spain
dc.contributor.funderNovartis
dc.date.accessioned2025-01-07T12:44:49Z
dc.date.available2025-01-07T12:44:49Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.1241
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420412372/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24898
dc.identifier.wosID573469101405
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Torrecárdenas
dc.page.numberS753-S753
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleRetrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Torrecárdenas

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía